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A 41 year-old female Gravida 5 Para 4014 presented with heavy
bleeding and pelvic pain with a known history of uterine leiomyomata.
She had a new partner and wanted to maintain her fertility. Physical
exam was notable for a 20 week size uterus with an 8 cm anterior
ﬁbroid. Ultrasound revealed a 7.8 cm × 7.1 cm uterine leiomyoma that
impinged on the cavity. An endometrial biopsy showed late secretory
endometrium. An abdominal myomectomy was performed via an
eight centimeter Pfannenstiel incision with excision of a 10 cm and a
4 cm uterine leiomyoma. The pelvic organs and peritoneal surfaces
were otherwise normal. After the surgery, the patient's uterus wasptotic cell necrosis and increasedmitotic activity with up to 9MF per 101. Introduction
According to the 2003 World Health Organization classiﬁcation,
uterine smooth muscle tumors that cannot be deﬁnitively diagnosed
as benign or malignant should be termed smooth muscle tumors of un-
certain malignant potential or STUMP (Hendrickson et al., 2003).
STUMPs are rare smooth muscle neoplasms with a clinical behavior be-
tween benign leiomyomas and frankly malignant leiomyosarcoma. Pa-
tients with leiomyomas, STUMPs, and leiomyosarcomas present with
similar clinical symptoms which include abnormal uterine bleeding,
pelvic pain, and pelvic pressure (Ip et al., 2010). Preoperative diagnosis
is based on ﬁndings of an enlarged uterus on pelvic examination and or
radiographic imaging. Conventional surgical treatment includes myo-
mectomy or hysterectomy. In women desiring fertility myomectomy
is commonly performed. Theﬁndingof a STUMP tumor inmyomectomy
specimens has been well described (Vilos et al., 2012). Pregnancy after
the diagnosis of a STUMP treated with myomectomy has not been pre-
viously reported. In the current casewe describe a successful pregnancy
after a preconceptually diagnosed STUMP. We present recommenda-
tions for counseling and management of patients with STUMPs who
desire fertility.s and Gynecology, Division of
Science Center at San Antonio,
tes.
. This is an open access article undernoted to be 10 week sized. Pathology of the smaller uterine tumor
showed a smooth muscle tumor with focal, mild, cytologic atypia, apo-
HPF (Figs. 1,2) consistent with diagnosis of STUMP. Immunohistochem-
ical staining for p53 and p16 was negative (Fig. 3). The patient
conceived spontaneously 6 months after her myomectomy. Her preg-
nancy was uncomplicated. She presented to labor and delivery at
37weeks in labor and underwent a repeat cesarean section and tubal li-
gation with delivery of a viable infant with APGARS 9 and 10 with a
weight of 3338 g. During the surgery, the surgeonswere unable to exte-
riorize the uterus due to suspected intramural and fundal myomas, and
pelvic adhesive disease. Two years from the initial diagnosis of STUMP
and one year since delivery, she underwent a total abdominal hysterec-
tomy without complications. The intraoperative ﬁndings included an
eight week size uterus, normal ovaries and fallopian tubes and no
evidence of metastatic disease. Final pathology showed no residual
STUMP. She is alive andwithout recurrent tumor 4 years fromher initial
diagnosis.3. Discussion
A literature search from January 1960 up to April 2015 was per-
formed in PubMed andMedline databases without language restriction.
All articles were initially screened for title and abstract and full texts of
eligible articles were subsequently selected. The search terms were
“smooth muscle tumor of uncertain malignant potential”, “pregnancy”,
“leiomyomata”, and “typical leiomyomata”.
Five case reports were found and are summarized in Table 1. In the
ﬁrst two cases the STUMPs were diagnosed during pregnancy andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Mild focal atypia and increased mitotic rate are seen (100×, hematoxylin & eosin). Fig. 3. Stump is ER positive, p16 and p53 negative (immunoperoxidase, 200×).
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3, 4, and 5 the smooth muscle tumors were not actually STUMPs, dem-
onstrating the difﬁculty with nomenclature of uterine smooth muscle
tumors. Bizarre leiomyomata and mitotically active leiomyomas are
variants of benign leiomyomatawith nomalignant potential and should
not be classiﬁed as STUMP (Ip et al., 2010; Downes &Hart, 1997). Differ-
ent types of smoothmuscle tumors are discussed in Table 2. The rarity of
pregnancy occurring after the diagnosis of STUMP is likely related to
advanced maternal age at diagnosis, infrequency of these tumors, and
the decision to have hysterectomy once the diagnosis of STUMP is
made. Our current case does show that pregnancy is possible after the
diagnosis of a STUMP.
The current case highlights the necessity of a multidisciplinaryman-
agement approach. The role of the gynecologic oncologist centers upon
counseling concerning the risk of STUMP recurrence. Depending on the
deﬁnition of STUMP used in the particular study, the recurrence rates
vary from 7.3 to 26.7% (Guntupalli et al., 2009; Peters et al., 1994). Ip
et al. performed an evaluation of all published studies that used the
same Stanford 3-feature diagnostic criteria for STUMP; cytologic atypia,
mitotic count, and coagulative tumor cell necrosis (CTCN) (Ip et al.,
2010). This review identiﬁed 91 cases of STUMP with 10 recurrences,
for a recurrence rate of 11%. Of the recurrences, 67% recurred as
leiomyosarcoma with signiﬁcant CTCN, and 80% had metastatic sites
out of the pelvis including lymphnodes, lung, bone, liver, and omentum.
The average time to recurrence was 51 months with a range of 15
months to 9 years. Speciﬁc information regarding the risk of STUMP
recurrence after treatment by myomectomy is provided in the review
by Vilos et al. (Ip et al., 2010). Among 76 patients with STUMP treated
with myomectomy, 5 (6.6%) experienced recurrence of disease. Several
observations can be made from these data. The majority of STUMP
recurrences reported in the literature had pathologic characteristics
consistent with a diagnosis of leiomyosarcoma (Ip et al., 2010; Yoon
et al., 2011). Recurrences following hysterectomy frequently involved
metastatic sites outside of the pelvis. However in patients who have
recurrence aftermyomectomy the recurrences are isolated to the uterus
in more than 50% of the cases. Isolated uterine recurrence after
myomectomy may actually represent “persistent disease” resulting
from incomplete excision of the STUMP. The majority of STUMP recur-
rences are classiﬁed as late recurrence occurring greater than 5 yearsFig. 2. Apoptotic necrosis is seen, no evidence of coagulative tumor cell necrosis (100×,
hematoxylin and eosin).from diagnosis. Fortunately the salvage rate for the patients who recur
is excellent with virtually all patients alive with disease or have no evi-
dence of disease. It is conceivable that a small subset of STUMPs
undergoes progression or malignant degeneration from STUMP to a
leiomyosarcoma similar to progression of serous borderline tumors
progressing to low grade serous adenocarcinoma (Dehari et al., 2007).
An alternative explanation is that a subset of the STUMPs which re-
curred was actually low grade leiomyosarcoma at initial diagnosis. The
late recurrences and excellent survival are consistent with the behavior
of low grade leiomyosarcoma (Veras et al., 2011). Certain histologic fea-
tures such as extensive CTCN should be considered a warning sign for
potential recurrence. Recent studies have suggested that the use of im-
munohistochemical stains, including p16 and p53 may help to identify
the STUMPs at greater risk of recurrence (Atkins et al., 2008; Ip et al.,
2009). Although cases of STUMPs with recurrence have been associated
with diffuse immunoreactivity for p16 and p53, the number of cases in
these studies is small, and further study is required to conﬁrm the
reliability of employing such markers. In the current case there was no
CTCN and immunohistochemistry showed negative staining for p16
and p53.
In those patients who desire fertility the risks of STUMP recurrence
must be weighed against the realistic expectation of pregnancy. Fortu-
nately most STUMPs have a favorable prognosis with a 5 year overall
survival rate of 92% (Peters et al., 1994). However, patients must also
be counseled that pregnancy is quite rare after the diagnosis of STUMP
likely due in part to advanced maternal age. At the current time there
is no reliable method to predict the clinical behavior of STUMPs. Based
on the available information several risk factors for recurrence can be
proposed including extensive CTCN, possibly the expression of p53
and p16, and incomplete excision at myomectomy. We recommend
thorough evaluation of the surgical material by a gynecologic patholo-
gist to assure leiomyosarcoma is ruled out. The surgical margins must
be carefully assessed in themyomectomy specimen as positive margins
could result in uterine recurrence or persistence. Adequate surgical
material should be available to the pathologist. Ideally the smoothmus-
cle lesion should be removed with the capsule intact. Extensive
morcellation of the specimens canmake pathologic assessment difﬁcult.
If there is uncertainty concerning the surgical margin consideration
should be given to re-operation with re-resection to assure negative
margins. Finally patients should be counseled that most recurrences
generally carry a good prognosis but deaths have been reported. The re-
current tumors frequently recur as leiomyosarcomawhich can be aggres-
sive tumors. With respect to surveillance we recommend surveillance
similar to that for uterine sarcoma. We recommend that a completion
hysterectomy be performed once childbearing is completed due to the
risk of late uterine recurrences. Evaluation for STUMP recurrence should
be performed before pregnancy is attempted. Treatment of recurrent
andmetastatic STUMPduring pregnancy should be avoided. As far as sur-
veillance for recurrence during pregnancy ionizing radiation should be
avoided. Imaging modalities that have been used to monitor uterine
leiomyomas during pregnancy include ultrasound andMRI, however dif-
ferentiation between leiomyomas, STUMPs, and leiomyosarcoma on im-
aging is not possible. In summary, good clinical outcomes for bothmother
Table 1
Literature review of STUMP in pregnancy.
Source Age Presentation Treatment Gross ﬁndings Microscopic
ﬁndings
Pregnancy outcome Follow up
Clauss et al.
(2010)
30 Incidental ﬁnding at
C-section
Myomectomy at time
of C-section
2.7 cm leiomyoma STUMP Live birth 27 weeks by C-section. 16 months NED
Vranjes et al.
(2011)
37 Uterine mass noted at 14
weeks EGA
Myomectomy at 18
weeks,
C-section at 33 weeks
35 cm fundal myoma-like
tumor, 4250 g
STUMP Live birth 33 weeks by
C-section-hysterectomy.
No residual
STUMP
Takeda et al.
(2011)
30 Abnormal uterine lesions
on ultrasound
Laparoscopic excision 4.3 cm tumor excised in
pieces, 20 g
Bizarre
leiomyoma
Conceived 7 months later.
Live birth 37 weeks by C-section
No data
Dgani et al.
(1998)
35 Prolapsed myoma Vaginal myomectomy Typical leiomyoma Mitotically active
leiomyoma
Conceived 3 months later. Live
birth.
N16 months NED
Downes &
Hart (1997)
ND Symptomatic ﬁbroid
uterus
Myomectomy Typical leiomyoma Bizarre
leiomyoma
2 subsequent live births by
C-section
73 months NED
Campbell et al. 40 Symptomatic ﬁbroid
uterus
Abdominal
myomectomy
10 cm and 4 cm
leiomyomas
STUMP Conceived 12 months later, Live
birth by C-section
Hysterectomy
no STUMP,
24 months NED
ND — no data; NED— no evidence of disease; EGA — estimated gestational age.
Table 2
Types of smooth muscle tumors.
Adapted from Dgani et al.
Diagnosis Atypia CTCN MF/10 HPF
Leiomyoma None–mild None 0–4
Leiomyoma with increased mitotic
activity
None–mild None Greater
than 5
Atypical leiomyoma Moderate–severe None 0–9
Smooth muscle tumor of uncertain
malignant potential
None–mild Present 0–9
Leiomyosarcoma None–mild Present Greater
than 10
Leiomyosarcoma Moderate–severe None Greater
than 10
Leiomyosarcoma Moderate–severe Present Any
CTCN: coagulative tumor cell necrosis; MF: mitotic ﬁgure; HPF: high power ﬁeld.
3J.E. Campbell et al. / Gynecologic Oncology Reports 15 (2016) 1–3andbaby arepossible after a fertility sparingmyomectomyand successful
pregnancy in a patient diagnosed preconceptually with a STUMP.
Written informed consent was obtained from the patient for
publication of this case report and accompanying images. A copy of
the written consent is available for review by the Editor-in-Chief of
this journal on request.
The authors have no conﬂicts of interest to disclose.
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